

Form PTO-1449

**INFORMATION DISCLOSURE CITATION  
IN AN APPLICATION**

(Use several sheets if necessary)

Docket Number (Optional)

TUU-P01-006

Application Number

09/628,225

Applicant  
Bacovchin et al.Filing Date  
July 28, 2000

Group Art Unit

654

**U.S. PATENT DOCUMENTS**

EXAMINER INITIAL	DOCUMENT NUMBER	DATE	NAME	CLASS	SUBCLASS	FILING DATE IF APPROPRIATE
	AA	6,011,155	1/4/00	Villhauer		
BR	AB	5,834,428	11/10/98	Drucker	514	12
	AC	5,631,224	5/20/97	Efendic et al.		
BR	AD	5,061,811	10/29/91	Pinori et al.	517	277
BR	AE	4,522,752	6/11/85	Sisto et al.	530	317

**FOREIGN PATENT DOCUMENTS**

	DOCUMENT NUMBER	DATE	COUNTRY	CLASS	SUBCLASS	Translation	
						YES	NO
	AF	WO 98/25644	6/18/98	PCT			
BR	AG	WO 97/40832	11/6/97	PCT			
	AH	WO 95/15309	6/8/95	PCT			
	AI	WO 93/08259	4/29/93	PCT			

**OTHER DOCUMENTS**

(Including Author, Title, Date, Pertinent Pages Etc.)

BR	AJ	Bell et al., 1983, "Exon duplication and divergence in the human preproglucagon gene", Nature 304(5924):368-71
BR	AK	Bell et al., 1983, "Hamster preproglucagon contains the sequence of glucagon and two related peptides", Nature 302(5910):716-8
BR	AL	Conlon, 1988, "Proglucagon-derived peptides: nomenclature, biosynthetic relationships and physiological roles", Diabetologia 31(8):563-6
BR	AM	Coruzzi et al., 1989, "Gastric antiseecretory activity of telenzepine, a new M1-selective muscarinic antagonist: comparison with pirenzepine", Arch Int Pharmacodyn Ther 302:232-41
BR	AN	Deacon et al., 1995, "Both subcutaneously and intravenously administered glucagon-like peptide I are rapidly degraded from the NH2-terminus in type II diabetic patients and in healthy subjects", Diabetes 44(9):1126-31
BR	AO	Dupre, 1991, "Influences of the gut on the endocrine pancreas" <u>The Endocrine Pancreas</u> (Raven Press, New York) pp 253-281
BR	AP	Ebert et al., 1987, "Gastrointestinal peptides and insulin secretion", Diabetes Met. Rev. 3:1-26
BR	AQ	Gutniak et al., 1992, "Antidiabetogenic effect of glucagon-like peptide-1 (7-36)amide in normal subjects and patients with diabetes mellitus", N Engl J Med 326(20):1316-22
BR	AR	Habener et al., 1991, "Biosyntheses of glucagon" <u>The Endocrine Pancreas</u> (Raven Press, New York) pp. 53-71
BR	AS	Holst et al., 1987, "Truncated glucagon-like peptide I, an insulin-releasing hormone from the distal gut", FEBS Lett. 211(2):169-74

8682294.1

Jeffrey E. Russell

April 22, 2003

Form PTO-1449

**INFORMATION DISCLOSURE CITATION  
IN AN APPLICATION**

(Use several sheets if necessary)

Docket Number (Optional)

TUU-P01-006

Applicant  
Bacovchin et al.

Filing Date

July 28, 2000

Application Number

09/628,225

Group Art Unit

1657

AT	Kawashima et al., 1990, "Pharmacological differentiation of presynaptic muscarinic receptors modulating acetylcholine release from postsynaptic muscarinic receptors in guinea-pig ileum", Gen Pharmacol 21(1):17-21
AU	Kinder et al., 1985, "Acylamino boronic acids and difluoroborane analogues of amino acids: potent inhibitors of chymotrypsin and elastase", J Med Chem 28(12):1917-25
AV	Kreymann et al., 1987, "Glucagon-like peptide-1 7-36: a physiological incretin in man", Lancet 2(8571):1300-4
AW	Kubiak et al., 1994, "Metabolism of mouse growth hormone-releasing factor, mGRF(1-42)OH, and selected analogs from the GRF series in mouse and bovine plasma in vitro", Pept Res 7(3):153-61
AX	Lambrech et al., 1989, "Pharmacology of hexahydro-difenidol, hexahydro-sila-difenidol and related selective muscarinic antagonists", Trends Pharmacol Sci 10(Suppl):60
AY	Lund et al., 1982, "Pancreatic preproglucagon cDNA contains two glucagon-related coding sequences arranged in tandem", Proc Natl Acad Sci U S A 79(2):345-9
AZ	Matteson et al., 1984, "Synthesis and properties of pinanediol $\alpha$ -amino boronic acids", Organometallics 3:1284
BA	Mojsov et al., 1986, "Preproglucagon gene expression in pancreas and intestine diversifies at the level of post-translational processing", J Biol Chem 261(25):11880-9
BB	Mojsov et al., 1987, "Insulinotropin: glucagon-like peptide I (7-37) co-encoded in the glucagon gene is a potent stimulator of insulin release in the perfused rat pancreas", J Clin Invest 79(2):616-9
BC	Mojsov, 1992, "Structural requirements for biological activity of glucagon-like peptide-I", Int J Pept Protein Res 40(3-4):333-43
BD	Orskov et al., 1987, "Pancreatic and intestinal processing of proglucagon in man", Diabetologia 30(11):874-81
BE	Patzelt et al., 1979, "Identification and processing of proglucagon in pancreatic islets", Nature 282(5736):260-6
BF	Pospisilik, John A. et al. Metabolism of Glucagon by Dipeptidyl Peptidase IV (CD26). <i>Regulatory Peptides</i> 96, 133-141 (2001).
BG	Radhakrishna et al., 1979, "New method for direct conversion of amides to amines", J Org Chem 44:1746
BH	Schmidt et al., 1985, "Glucagon-like peptide-1 but not glucagon-like peptide-2 stimulates insulin release from isolated rat pancreatic islets", Diabetologia 28(9):704-7
BI	Shue et al., 1987, "Amide bond surrogates: a general synthetic route to trans carbon-carbon double bond isosteres", Tetrahedron Letters 28:3225
BJ	Stanley et al., 1989, "Repeated hypothalamic stimulation with neuropeptide Y increases daily carbohydrate and fat intake and body weight gain in female rats", Physiol Behav 46(2) 173-7

Jeffrey E. Russell

April 22, 2003

Form PTO-1449		Docket Number (Optional) TUU-P01-006		Application Number 09/628,225	
<b>INFORMATION DISCLOSURE CITATION</b> <b>IN AN APPLICATION</b> <i>(Use several sheets if necessary)</i>		Applicant Bacovchin et al.		<b>RECEIVED</b> <b>TECH CENTER 1600/2900</b> <b>MAR 14 2002</b>	
		Filing Date July 28, 2000			
BK		Weir et al., 1989, "Glucagonlike peptide I (7-37) actions on endocrine pancreas", Diabetes 38(3):338-42			
BL		Wilding et al., 1992, "Increased neuropeptide Y content in individual hypothalamic nuclei, but not neuropeptide Y mRNA, in diet-induced obesity in rats", J Endocrinol 132(2):299-304			
EXAMINER		Jeffrey E. Russel		DATE CONSIDERED April 22, 2003	
EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPEP § 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to the applicant					

Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

(Use several sheets if necessary)

MAY 28 2002

Docket Number (Optional)

TUU-PO1-006

Applicant

Bachovchin et al.

Filing Date

July 28, 2000

Application Number

09/628.225

Group Art Unit

1653

## U.S. PATENT DOCUMENTS

RECEIVED	
JUN 14 2002	
TECH CENTER 1600/2900	
SUBCLASS	Translation
	RES
	N

## FOREIGN PATENT DOCUMENTS

	DOCUMENT NUMBER		DATE	COUNTRY	CLASS	SUBCLASS	Translation	
							YES	NO
<i>JSR</i>	AA	WO 98/19998	5/14/98	PCT	_____	_____		
<i>JSR</i>	AB	WO 96/14857	5/23/96	PCT	_____	_____		
<i>JSR</i>	AC	WO 89/03223	4/20/89	PCT	_____	_____		

## OTHER DOCUMENTS

(Including Author, Title, Date, Pertinent Pages Etc.)

AD	Balkan et al. Improved insulin secretion and oral glucose tolerance after in vivo inhibition of DPP-IV in obese Zucker rats. <i>Diabetologia</i> Suppl. 40, A131 Abstract (1997).
AE	Coutts et al. Structure-Activity Relationships of Boronic Acid Inhibitors of Dipeptidyl Peptidase IV. 1. Variation of the P2 Position of Xaa-boroPro Dipeptides. <i>J. Med. Chem.</i> 39, 2087-2094 (1996).
AF	Deacon et al. Degradation of Glucagon-Like Peptide-1 by Human Plasma in Vitro Yields an N-Terminally Truncated Peptide that is a Major Endogenous Metabolite in Vivo. <i>J. Clin. Endocrin.</i> 83, 952-957 (1995).
AG	Holst, J. J. & Deacon, C. F. Inhibition of the Activity of Dipeptidyl-Peptidase IV as a Treatment for Type 2 Diabetes. <i>Diabetes</i> 47, 1663-1670 (1998).
AH	Kieffer et al. Degradation of Glucose-Dependent Insulinotropic Polypeptide and Truncated Glucagon-Like Peptide 1 in Vitro and in Vivo by Dipeptidyl Peptidase IV. <i>Endocrin.</i> 136, 3585-3596 (1995).
AI	Mentlein et al. Dipeptidyl-peptidase IV hydrolyses gastric inhibitory polypeptide, glucagons-like peptide-1(7-36)amide, peptide histidine methionine and is responsible for their degradation in human serum. <i>Eur. J. Biochem.</i> 214, 829-835 (1993).
AJ	Mentlein et al. Proteolytic processing of neuropeptide Y and peptide YY by dipeptidyl peptidase IV. <i>Regulatory Peptides</i> 49, 133-144 (10 December 1993).
AK	Pederson et al. Improved Glucose Tolerance in Zucker Fatty Rats by Oral Administration of the Dipeptidyl Peptidase IV Inhibitor Isoleucine Thiazolidide. <i>Diabetes</i> 47, 1253-1258 (August 1998).

EXAMINER

Jeffrey E. Russell

DATE CONSIDERED \_\_\_\_\_

April 21, 2003

EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPEP § 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to the applicant.